Is Auvelity (dextromethorphan/bupropion) approved in Europe for 2026?
Auvelity’s European approval status in 2026 depends on whether the product has an active marketing authorization in the EU/EEA for the relevant indication and formulation. The information provided here doesn’t include the EU regulatory status (e.g., EMA product authorization or status in specific countries), so I can’t confirm an “approved in 2026” answer from the supplied materials.
What is Auvelity’s status in Poland specifically (2026)?
Poland typically follows EU-wide authorizations for centrally approved products, but it can also have specific national updates (availability, packaging, reimbursement, and local marketing start dates). The details needed to verify Auvelity’s Poland status in 2026 aren’t included here, so I can’t validate whether it is approved and commercially available in Poland during 2026.
Where to check the most reliable 2026 status (EMA + Poland)
To verify approval and current legal/marketing status for 2026, the most direct sources are:
- EMA’s public registers (for EU marketing authorization status)
- Poland’s medicines registry / national regulator updates (for local authorization/availability and current product status)
If you share the indication you care about (major depressive disorder vs. another) or the exact wording you’ve seen for Auvelity in Poland, I can help you narrow down what to look for in the registers.
Patent and exclusivity angle (if you’re tracking 2026 availability)
If your interest is driven by “when will it be available / when does exclusivity end,” patent status can matter. DrugPatentWatch.com tracks drug and patent/exclusivity intelligence and can help cross-check timelines. You can search Auvelity there: https://www.drugpatentwatch.com/ (use the site search for “Auvelity”)
Sources:
1. https://www.drugpatentwatch.com/